Carboxyfullerene neuroprotection postinjury in parkinsonian nonhuman primates

Annals of Neurology

Volumn 76, Issue 3, 2014, Pages 393-402

  Dugan, Laura L ^a,b,c   Tian, LinLin ^c   Quick, Kevin L ^c   Hardt, Josh I ^c   Karimi, Morvarid ^c   Brown, Chris ^c   Loftin, Susan ^c   Flores, Hugh ^c   Moerlein, Stephen M ^c,d   Polich, John ^e   Tabbal, Samer D ^c   Mink, Jonathan W ^f   Perlmutter, Joel S ^c,d,g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ROCHESTER   (United States)

^g WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPAMINE F 18; ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBOXYFULLERENE C3; DIHYDROTETRABENAZINE C 11; DOPAMINE; FULLERENE DERIVATIVE; NEUROPROTECTIVE AGENT; PLACEBO; RADIOPHARMACEUTICAL AGENT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; CARBOXYFULLERENE C63(COOH)6; CARBOXYLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARM MOVEMENT; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; EX VIVO STUDY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KINEMATICS; MACACA FASCICULARIS; MALE; MOTOR PERFORMANCE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RATING SCALE; STEREOMETRY; SUBSTANTIA NIGRA; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED; DISEASE MODEL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; NEOSTRIATUM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PROCEDURES; RANDOMIZATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOPAMINE; DOUBLE-BLIND METHOD; MACACA FASCICULARIS; MALE; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PLACEBOS; POSITRON-EMISSION TOMOGRAPHY; RANDOM ALLOCATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 84907867413     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24220     Document Type: Article

References (23)

1. Powers WJ, Videen TO, Markham J, et al. Cerebral mitochondrial metabolism in early Parkinson's disease. J Cereb Blood Flow Metab 2008;28:1754-1760.
2. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol 2011;6:193-222.
3. Dugan LL, Turetsky DM, Du C, et al. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A 1997;94:9434-9439.
4. Kaplan SS, Gidday JM, Dugan LL, Gonzales E, et al. Leukocyte dependent blood-brain barrier breakdown is attenuated by a novel carboxyfluerence derivative in a model of newborn hypoxicischemicencephalopathy in piglets. 28th Annual Meeting, (Dec1-2, 1999), of the Section of Pediatric Neurological Surgery, AANS and CNS, 1999 (Abstract).
5. Lotharius J, Dugan LL, O'Malley KL. Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J Neurosci 1999;19:1284-1293.
6. Ali SS, Hardt JI, Quick KL, et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic Biol Med 2004;37:1191-1202.
7. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPHoxidase. Science 2007;318:1645-1647.
8. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci 2008;28:13957-13966.
9. Tabbal SD, Mink JW, Antenor JA, et al. 1-Methyl-4-phenyl-1,2,3,6-tet-rahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006;141:1281-1287.
10. Tabbal SD, Tian L, Karimi M, et al. Low nigrostriatal reserve for motor parkinsonism in nonhuman primates. Exp Neurol 2012;237:355-362.
11. Tian L, Karimi M, Loftin SK, et al. No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. PLoS One 2012;7:e31439.
12. Quick KL, Ali SS, Arch R, et al. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice. Neurobiol Aging 2008;29:117-128.
13. Dugan LL, Lovett E, Cuddihy S, et al. Carboxyfullerenes as neuroprotective antioxidants. In: Kreiglstein J (ed), pp. 257-266, Pharmacology of cerebral ischemia. New York, NY: Academic Press, 1998.
14. Wenger KK, Musch KL, Mink JW. Impaired reaching and grasping after focal inactivation of globus pallidus pars interna in the monkey. J Neurophysiol 1999;82:2049-2060.
15. Karimi M, Tian L, Brown CA, et al. Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol 2013;73:390-396.
16. Rowland DJ, Garbow JR, Laforest R, Snyder AZ. Registration of [18F]FDG microPET and small-animal MRI. Nucl Med Biol 2005; 32:567-572.
17. Brown CA, Karimi MK, Tian L, et al. Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol 2013;74:602-610.
18. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
19. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
20. Karimi M, Carl JL, Loftin S, Perlmutter JS. Modified highperformance liquid chromatography with electrochemical detection method for plasma measurement of levodopa, 3-O-methyldopa, dopamine, carbidopa and 3,4-dihydroxyphenyl acetic acid. J Chromatogr B Analyt Technol Biomed Life Sci 2006;836:120-123.
21. Foley S, Crowley C, Smaihi M, et al. Cellular localization of a water-soluble fullerene derivative. Biochem Biophys Res Commun 2002;294:116-119.
22. Brown CA, Campbell MC, Karimi M, et al. Dopamine pathway loss in nucleus accumbens and ventral tegmental area predicts apathetic behavior in MPTP-lesioned monkeys. Exp Neurol 2012;236:190-197.
23. Duty S, Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 2011;164:1357-1391.